Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Residual cardiovascular risk persists despite statins, yet outcome studies of lipid‐targeted therapies beyond low‐density lipoprotein cholesterol (LDL‐C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for cardiovascular events. High‐dose eicosapentaenoic ac...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cardiol
Main Authors: Bhatt, Deepak L., Steg, Ph. Gabriel, Brinton, Eliot A., Jacobson, Terry A., Miller, Michael, Tardif, Jean‐Claude, Ketchum, Steven B., Doyle, Ralph T., Murphy, Sabina A., Soni, Paresh N., Braeckman, Rene A., Juliano, Rebecca A., Ballantyne, Christie M.
Formato: Artigo
Idioma:Inglês
Publicado: Wiley Periodicals, Inc. 2017
Assuntos:
Trial Designs
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5396348/
https://ncbi.nlm.nih.gov/pubmed/28294373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22692
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares